illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Royalty Pharma
Company logo

Royalty Pharma | Sustainability Performance

https://www.royaltypharma.com/

Invests in and manages pharmaceutical royalties and intellectual property. Activities include acquiring rights to drug products, monitoring revenue streams, and managing legal and regulatory obligations, while providing capital to support ongoing development projects.

1996

United States

51 - 200 employees

Biotechnology

$1B - 10B in revenue

$500M - 1B in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#9587
Overall
#2140
in United States
#201
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

149 out of 245

Overview
Environmental
Carbon emissionsNature and biodiversityClimate risk
Social
Diversity and InclusionPay GapsExternalities
Governance
TargetsSDG ImpactESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Arcturus Therapeutics

United States, Health Care, Biotechnology


Company logo
Pivot Bio

United States, Health Care, Biotechnology


Company logo
Cumberland Pharmaceuticals

United States, Health Care, Pharmaceuticals

Female employees

50% 2024
Laggard

Externalities

101.0K $, 2024
Leading

Market cap

31.6B $, 2026▼39.9% YoY

Revenue

2.4B $, 2025▼4.8% YoY

R&D intensity

19.01% 2025

Female employees

Reveal data for 1 credit

Share of female employees (%)

25
50
75
100
Company
Benchmark
Powered by illuminem and GIST Impact

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Royalty Pharma plc, US/Dublin pharma royalty investment major, has faced multiple US shareholder class actions over alleged inadequate disclosure of multiple biotech royalty investment customer concentration risks affecting Royalty Pharma's share price, plus periodic SEC enforcement scrutiny on alleged inadequate disclosure of competitive market displacement affecting US institutional shareholders.
Powered by illuminem

Carbon emissions breakdown

Reveal data for 2 credits

KPIMetricYear
20202021202220232024Benchmark
**************-***********************************
**************-***********************************
Powered by illuminem and GIST Impact

Climate risk

OverallAcuteChronic
Reveal data for 20 credits
Unlock Acute & Chronic
5 assets assessed
ScenarioComing soon
44Moderate
$187.3Bestimated revenue at risk
Thematic risk scoresESRS aligned scoresComing soon
Download Climate Risk AnalysisPowered by illuminem and GIST impact

Biodiversity loss in km²

Reveal data for 2 credits

Biodiversity loss in terms of the equivalent land affected (km²e)

Total biodiversity loss (km²e)
Industry benchmark
Powered by GIST and illuminem

Biodiversity loss in CO2e

Reveal data for 2 credits

Total biodiversity loss as CO2e tonnes

Total biodiversity loss (CO2e tonnes)
Industry benchmark

Powered by GIST and illuminem

Potential species loss

Reveal data for 2 credits

Estimated nature species lost due to corporate activity, expressed as Potentially Disappeared Fraction (PDF)

One row per year, with the latest at the top. Each driver uses its own scale.

Low ImpactHigh Impact
Industry benchmark
Powered by GIST and illuminem

Biodiversity impact

Reveal data for 2 credits

KPIMetricYear
20202021202220232024Benchmark
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
Powered by illuminem and GIST Impact
PDF: Potentially Disappeared Fraction (of species) due to corporate activities

Land use

Reveal data for 2 credits

KPIMetricYear
InfinityInfinityInfinityInfinityInfinityBenchmark
**************-----*******
**************-----*******
**************-----*******
**************-----*******
**************-----*******
Powered by illuminem and GIST Impact

Diversity & inclusion

Reveal data for 3 credits

KPIMetricYear
20202021202220232024Benchmark
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
Powered by illuminem and GIST Impact

Pay gap breakdown

Reveal data for 1 credit

KPIMetricYear
20202021202220232024Benchmark
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
**************---*********************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
**************-----*******
********************************************************
********************************************************
Powered by illuminem and GIST Impact

Externalities

Reveal data for 1 credit

KPIMetricYear
20202021202220232024Benchmark
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
Powered by illuminem and GIST Impact

Market cap

31.6B $, 2026▼39.9% YoY

Revenue

2.4B $, FY2025▼4.8% YoY

EBITDA

1.6B $, FY2025▼9.1% YoY

Operating margin

66% Industry: -8722▼12.9% YoY

P/E ratio

28.3 Industry: 6▼37.6% YoY

Revenue & EBITDA

$2.4BFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

792.1M 2025▼66.8% YoY

Capex

1.7B 2025▲47.6% YoY

Debt/equity ratio

1.4 Industry: 2▼NaN% YoY

R&D intensity

19.0%FY2025

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

5.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

2.4

▼ 17.3%

2023

2.3

▼ 15.6%

2024

2.4

▼ 24.8%

2025

5.2

2031

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Available

Recycling policy

Not available

Workplace health & safety policy

Available

64%
Independent Directors

9 out of 14 incl. management

Powered by illuminem

Overall score

52

Environment

24

Social

82

Governance

50

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

SDG impact

Reveal data for 5 credits
2024

Powered by illuminem and GIST Impact

SDG impact (historical)

Reveal data for 5 credits

KPIMetricYear
20192020202120222023Benchmark
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
********************************************************
Powered by illuminem and GIST Impact

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees



    Available in
    Scale package

    Access
  • Email

  • Email